Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

By sjmartinez • June 13, 2023

Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jun 12:ard-2023-223916. doi: 10.1136/ard-2023-223916. Epub ahead of print. PMID: 37308218.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, methotrexate, Publications, Rheumatology, tumor necrosis factor inhibitors

Clinical Outcomes and Health Care Costs in Patients Hospitalized With Heart Failure and Transthyretin Amyloid Cardiomyopathy: Findings From GWTG-HF

Shoji S, Ikeaba U, Fonarow GC, Selvaraj S, Lewsey SC, Pandey A, Khouri MG, Alhanti B, McDermott JJ, Wright J, Vaduganathan M, Greene SJ. Clinical[...]

A practical approach to Cardiopulmonary Exercise Testing: from functional evaluation to adapted exercise prescription

Neunhaeuserer D, Gevaert AB, Hansen D, Battista F, Bauer P, Davos CH, Ermolao A, Sanz-de la Garza M, Guazzi M, Howden EJ, Laukkanen J, Mueller-Stegner[...]

Gut microbe-generated metabolite trimethylamine N-oxide and risk of abdominal aortic aneurysm: a cohort study

Li XS, Wang M, Wang Z, Fan B, Tian MY, Filippazzo J, Lee Y, Mallela DP, Mao K, Liu Y, Lemaitre RN, Xie V, Diaz[...]